Developmental regulation of HBV biosynthesis by Ten-eleven translocation (Tet) methylcytosine dioxygenases
Developmental regulation of HBV biosynthesis by Ten-eleven translocation (Tet) methylcytosine dioxygenases
批准号:
10733902
负责人:
Alan McLachlan
金额:
$39.12万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-06-09 至 2028-05-31
关键词:
AcuteAdultAnabolismAntiviral TherapyBiological ModelsCapsidCell NucleusCell TherapyCessation of lifeChromatin StructureChromosome DeletionChronicChronic Hepatitis BCircular DNAClinicalCytoplasmDNADNA MethylationDNA sequencingDevelopmentDioxygenasesEpigenetic ProcessGene SilencingGeneticGenetic TranscriptionGenomeGenomic DNAGenomicsGrantHealthHepatitis B VirusHistonesIndividualLife Cycle StagesLiverLoxP-flanked alleleMediatingMethylationMolecularMolecular WeightMusNuclearNucleotidesPhysiologicalPhysiologyPredispositionProtein translocationProteinsRNARegulationResolutionReverse TranscriptionRoleSignal TransductionSuggestionSystemTamoxifenTransgenesTransgenic MiceViralViral GenomeViral Load resultVirus DiseasesVirus InactivationVirus IntegrationVirus Replicationbisulfitecellular targetingchronic liver diseasedemethylationdesigneffective therapyhuman pathogenin vivoinhibitor therapyliver developmentliver functionmouse modelnew therapeutic targetnovelnovel strategiespostnatalpreventrecombinasetargeted treatmenttherapeutic target
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary and Relevance.
Hepatitis B virus (HBV) infection is a worldwide health problem. It is estimated that there are 200 to 500 million
HBV chronic carriers in the world for whom, to date, there is no reliable treatment. HBV causes both acute and
chronic liver disease and is responsible for an estimated one million deaths annually. Currently available
therapies reduce viral loads but fail to resolve chronic HBV infections. Therefore, effective treatments for chronic
HBV infection are urgently required. The major obstacle to the resolution of chronic HBV infections is the
eradication or inactivation of nuclear HBV covalently closed circular (ccc) DNA which is the template for viral
transcription. To this end, we have developed HNF1α-null HBV transgenic mice and liver-specific Tet-deficient
HBV transgenic mice. HNF1α-null HBV transgenic mice synthesize nuclear HBV cccDNA, a fraction of which is
extensively methylated in adult mice. Liver-specific Tet-deficient HBV transgenic mice are viable, essentially
display normal liver physiology, but lack detectable HBV transcription and replication (i.e. they are effectively
“cured”) suggesting Tet is also essential for viral biosynthesis. The observation that Tet-deficient HBV transgenic
mice fail to support HBV biosynthesis is consistent with the suggestion that Tet is essential for the developmental
demethylation of HBV genomic DNA which epigenetically governs HBV transcription by modulating viral
chromatin structure in vivo. Defining the precise temporal requirements for Tet expression associated with HBV
transcription and replication will indicate the liver developmental stages when viral biosynthesis is susceptible to
inhibition by Tet deficiency. This will be achieved by modulating Tet expression using our recently developed
tamoxifen-inducible Tet-deficient HBV transgenic mouse model system. Using this system, the developmental
control of HBV transcription, viral biosynthesis and HBV DNA methylation by Tet expression will be established
and correlated with the epigenetic histone marks and chromatin structure associated with the HBV genome.
Similar studies will be performed using the HNF1α-null Tet-deficient HBV transgenic mouse model of chronic
viral infection so the developmental control of HBV transcription, viral biosynthesis, HBV DNA methylation,
epigenetic histone marks and chromatin structure by Tet expression associated with the HBV genome can be
compared between the HBV transgene DNA and the nuclear HBV cccDNA. Finally, the development of HBV
transgenic mice supporting viral biosynthesis exclusively from extrachromosomal genomic DNA, a more
physiologically relevant mouse model of chronic viral infection, will be developed so the effect of Tet-deficiency
on HBV biosynthesis derived solely from HBV cccDNA can be determined. Defining the molecular signals
responsible for the loss of HBV biosynthesis due to Tet deficiency may lead to the identification of cellular
therapeutic targets, including but not restricted to Tet proteins, that are amenable to the development of novel
small molecular weight therapeutic inhibitors to resolve rather than simply treat chronic HBV infection.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Liver lobule zonation, hepatocellular carcinoma (HCC) and β-catenin mediated hepatitis B virus (HBV) biosynthesis
-
批准号:9884339
-
项目类别:
-
资助金额:$36.58万
-
财政年份:2019
-
负责人:Alan McLachlan
-
依托单位:
Liver lobule zonation, hepatocellular carcinoma (HCC) and β-catenin mediated hepatitis B virus (HBV) biosynthesis
-
批准号:10059188
-
项目类别:
-
资助金额:$36.58万
-
财政年份:2019
-
负责人:Alan McLachlan
-
依托单位:
Liver lobule zonation, hepatocellular carcinoma (HCC) and β-catenin mediated hepatitis B virus (HBV) biosynthesis
-
批准号:10523111
-
项目类别:
-
资助金额:$35.85万
-
财政年份:2019
-
负责人:Alan McLachlan
-
依托单位:
Liver lobule zonation, hepatocellular carcinoma (HCC) and β-catenin mediated hepatitis B virus (HBV) biosynthesis
-
批准号:10297857
-
项目类别:
-
资助金额:$35.85万
-
财政年份:2019
-
负责人:Alan McLachlan
-
依托单位:
Developmental regulation of HBV biosynthesis by FoxA and DNA methylation
-
批准号:9906839
-
项目类别:
-
资助金额:$39.98万
-
财政年份:2016
-
负责人:Alan McLachlan
-
依托单位:
Developmental regulation of HBV biosynthesis by FoxA and DNA methylation
-
批准号:9275362
-
项目类别:
-
资助金额:$39.98万
-
财政年份:2016
-
负责人:Alan McLachlan
-
依托单位:
Developmental regulation of HBV biosynthesis by FoxA and DNA methylation
-
批准号:9156108
-
项目类别:
-
资助金额:$39.97万
-
财政年份:2016
-
负责人:Alan McLachlan
-
依托单位:
Discovery of novel anti-HBV compounds targeting host factors
-
批准号:8731770
-
项目类别:
-
资助金额:$19.76万
-
财政年份:2013
-
负责人:Alan McLachlan
-
依托单位:
Discovery of novel anti-HBV compounds targeting host factors
-
批准号:8445098
-
项目类别:
-
资助金额:$22.21万
-
财政年份:2013
-
负责人:Alan McLachlan
-
依托单位:
Initiation of Hepatitis B Virus Replication
-
批准号:6771037
-
项目类别:
-
资助金额:$9.39万
-
财政年份:2003
-
负责人:Alan McLachlan
-
依托单位:
Initiation of Hepatitis B Virus Replication
-
批准号:6660195
-
项目类别:
-
资助金额:$9.39万
-
财政年份:2003
-
负责人:Alan McLachlan
-
依托单位:
Regulation of Hepatitis B Virus Transcription
-
批准号:6572137
-
项目类别:
-
资助金额:$63.34万
-
财政年份:2003
-
负责人:Alan McLachlan
-
依托单位:
HEPATITIS B VIRUS
-
批准号:6307373
-
项目类别:
-
资助金额:$2.74万
-
财政年份:1999
-
负责人:Alan McLachlan
-
依托单位:
HEPATITIS B VIRUS
-
批准号:6118081
-
项目类别:
-
资助金额:$2.74万
-
财政年份:1998
-
负责人:Alan McLachlan
-
依托单位:
HEPATITIS B VIRUS
-
批准号:6279276
-
项目类别:
-
资助金额:$2.73万
-
财政年份:1997
-
负责人:Alan McLachlan
-
依托单位:
HEPATITIS B VIRUS
-
批准号:6249228
-
项目类别:
-
资助金额:$2.41万
-
财政年份:1997
-
负责人:Alan McLachlan
-
依托单位:
REGULATION OF HEPATITIS B VIRUS TRANSCRIPTION
-
批准号:2065428
-
项目类别:
-
资助金额:$30.17万
-
财政年份:1991
-
负责人:Alan McLachlan
-
依托单位:
REGULATION OF HEPATITIS B VIRUS TRANSCRIPTION
-
批准号:2837410
-
项目类别:
-
资助金额:$52.64万
-
财政年份:1991
-
负责人:Alan McLachlan
-
依托单位:
REGULATION OF HEPATITIS B VIRUS TRANSCRIPTION
-
批准号:6328700
-
项目类别:
-
资助金额:$55.84万
-
财政年份:1991
-
负责人:Alan McLachlan
-
依托单位:
Regulation of Hepatitis B Virus Transcription
-
批准号:6846320
-
项目类别:
-
资助金额:$9.02万
-
财政年份:1991
-
负责人:Alan McLachlan
-
依托单位:
海外基金